Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Decoy-20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Decoy-20 overview

Decoy-20 is under development for the treatment of solid tumors including colorectal cancer, pancreatic cancer, bladder carcinoma, breast cancer, cervical cancer, non-Hodgkin lymphoma and hepatocellular carcinoma-associated HBV infection and human immunodeficiency virus (HIV) infection. It comprises of a single strain of killed and intact, non-pathogenic gram bacteria with reduced LPS-endotoxin activity. it is administered through intravenous route.

Indaptus Therapeutics overview

Indaptus Therapeutics (Indaptus) operates as a clinical stage biopharmaceutical company. Indaptus is headquareterd in New York City, New York, the US.

For a complete picture of Decoy-20’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.